MolecularHUB will be retiring on August 1st, 2015. Please backup any data. Web access and all uploaded data will become unavailable when MolecularHUB is decommissioned on August 1st, 2015.
Find information on common issues.
Ask questions and find answers from other users.
Suggest a new site feature or improvement.
Check on status of your tickets.
Taking molecular sciences to the next level through co-creation and collaboration
28 Feb 2013
Neuromyelitis optica (NMO) is a rare autoimmune inflammatory demyelinating disease that targets the optic nerve and the spinal cord. It is often misdiagnosed as multiple sclerosis (MS) as there are no biomarkers to distinguish between the two. NMO does not often present with lesions or inflammation of the brain as MS does. It is important to diagnose the disorder correctly as they have different treatments for optimal results. A possible new marker (NMO-IgG) for neuromyelitis optica has been tested as a distinguishing marker between NMO and MS. A study (Lennon, Vanda A., Dean M Wingerchuk, Thomas J Kryzer, Sean J Pittock, Claudia F Lucchinetti, Kazuo Fujihara, Ichiro Nakashima, Brian G Weinshenker. “A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis.” The Lancet 364: 9451(2004)2106-2112.) NMO-IgG was found in three-quarters of patients that have been diagnosed with NMO and in no patients with classic MS. Have there been any more studies done on this new biomarker to support the findings of this study? If so, has it been set into motion to become a diagnostic tool in hospitals?
You must be logged in to comment.
Please keep comments polite and on topic. Offensive posts may be removed.
© 2013 MolecularHUB. The MolecularHUB name, associated trade marks and logos are trade marks of MolecularHUB.